Two strategies for multiplying SKUs: Hims multiplies through “personalized” formulations of one molecule; Orderly multiplies through formats and dose tiers — and both multiplications are where pricing truth goes to hide.
The two models
Hims is the category’s marketing heavyweight with its most contested model: after its Novo Nordisk partnership collapsed in June 2025, it leaned into “personalized” compounded semaglutide — the legal rationale regulators and manufacturers dispute most directly. Advertised entry prices are aggressive; true maintenance-dose totals are exactly what our pending verification exists to establish.
Orderly Meds competes on format breadth — injectables plus oral formats across multiple dose tiers — which makes it a natural comparison shop but also multiplies the price-table complexity where teaser structures hide. Its dose-tier pricing is queued for verification; oral-format claims inherit our standing evidence caveats.
Verified vs pending — read this before the marketing
Neither provider on this page has completed price verification, so this comparison stays structural — business models, pricing architecture, and the questions each must answer — with zero advertised numbers repeated as facts. The only verified figures on this site today sit in the ledger.
Complexity as a pricing instrument
Every added variant — a tweaked “personalized” dose, another oral tier — creates one more cell in a price table most shoppers never fully see, and one more place an entry price can differ from a maintenance price. That’s not an accusation of either company; it’s why our verification protocol prices every tier at maintenance dose before a single figure is repeated, and why the teaser file should be read before either checkout.
Go deeper
Full files: Hims · Orderly Meds. Decision tools: the quiz routes by coverage and priorities; the calculator turns any quote into a true 12-month number; the ledger holds every verified figure and every pending slot.